PapersPMID:21939549
Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“Chamomile had no significant effect on differences in either the BDI (p = 0.60) or the trait subscale of the STAI (p = 0.45).”
- Study
- RCT
- Duration
- 4 weeks
- Dose studied
- 270 mg twice daily (540 mg/day), one dose between lunch and dinner and one about an hour before bed
- Population
- adults aged 18-65 with DSM-IV chronic primary insomnia of at least 6 months, current mood or anxiety disorder excluded
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Adults aged 18 to 65 with DSM-IV primary insomnia for at least 6 months
- Participants
- 34
- Comparator
- placebo
- Duration
- 28 days
- Endpoints measured
- 16